DEA and HHS Extend Telemedicine Flexibilities through 2025

November 15, 2024

The Drug Enforcement Administration (DEA) in concert with the Department of Health and Human Services (HHS) issued a third extension of telemedicine flexibilities for the prescribing of controlled medications, through December 31, 2025.

In 2023, in response to a set of proposed telemedicine rules, DEA received more than 38,000 comments and held two days of public listening sessions. In light of that feedback and discussion, and to give DEA time to consider a new path forward for telemedicine, DEA and the Department of Health and Human Services (HHS) extended current telemedicine flexibilities through the end of 2024.

DEA and HHS continue to carefully consider the input received and are working to promulgate a final set of telemedicine regulations. However, with the end of 2024 quickly approaching, DEA, jointly with HHS, has extended current telemedicine flexibilities through December 31, 2025.

Full text of the extension "Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications."